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Bovine parathyroid chromogranin A inhibits the cleavage of Z-Ala-Lys-Arg-AMC by either trypsin or 
IRCM-serine protease 1 (IRCM-SPl), a putative novel processing enzyme originally isolated from porcine 
pituitary anterior and neurointermediate lobes. On larger substrates, chromogranin A is a reversible com- 
petitive inhibitor of the cleavage at pairs of basic amino acids by IRCM-SPl. The substrates tested included 
pituitary ACTH and adrenal medulla pro-enkephalin-derived peptides such as the 8.6 kDa synenkephalin- 
containing precursor and peptide B. Chromogranin A is itself selectively processed by IRCM-SPl, and 
ACTH was shown to compete for such cleavage. These data suggest that chromogranins as a class of acidic 
proteins could participate in the tissue-specific processing of pro-hormones. 
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1. INTRODUCTION 
Recently, a novel enzyme called IRCM-serine 
protease 1 (IRCM-SPl) was isolated and 
characterized from porcine pituitary anterior and 
neurointermediate lobes [l-3], and from rat heart 
atria and ventricles [4]. The enzyme is a 
homodimer and has a subunit structure consisting 
of two polypeptide chains linked together by a 
disulfide bridge(s) typical of regulatory serine pro- 
teases [5]. The cleavage specificity of this protease 
was studied using a variety of peptides including 
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tripeptide fluorogenic substrates and larger natural 
peptide substrates derived from pro-opio- 
melanocortin (POMC) [3,4] or pro-atria1 
natriuretic factor (Pro-ANF) [4]. These data 
demonstrated the remarkable ability of IRCM-SPl 
to cleave selectively all these substrates at specific 
basic amino acids, including both single and pairs 
of basic residues, known to be cleaved in vivo 
[3,4]. The fact that this enzyme in vitro cleaves all 
the bonds known to be cleaved in vivo in various 
pro-hormone precursors suggests that there must 
be an additional mechanism for tissue-specific dif- 
ferential processing of pro-hormones, which is 
known to occur for a number of precursors [6]. 
This process may be due to a kinetic phenomenon 
reflecting differential contact time with active en- 
zyme and/or differing enzyme :substrate ratios 
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[3,4]. Another possibility is the tissue-specific 
presence of varying amounts of a general process- 
ing enzyme modulator or reversible inhibitor. Such 
a putative factor(s) would interact with either pro- 
hormones and/or their processing enzyme(s) 
thereby selectively modulating the cleavage sen- 
sitivity of these precursors, thus regulating post- 
translational hormone biosynthesis. 
Chromogranins A, B and C represent a family 
of closely related, but distinct, acidic proteins 
found in secretory granules derived from en- 
docrine and neuroendocrine cells [7-g]. The 
cDNA sequence coding for chromogranin A, the 
most abundant member of the family, has recently 
been reported, [lO,l I]. Although the chromo- 
granins have been shown to bind Ca2+ [12], their 
exact physiological role has not yet been defined. 
Their possible participation in pro-hormone 
vesicular packaging and/or sorting has been pro- 
posed [7-l I], but not proven. The present work 
demonstrates that chromogranin A is a reversible 
competitive inhibitor of IRCM-SPl cleavage at 
pairs of basic amino acids in a number of pro- 
hormone substrates derived from either POMC or 
pro-enkephalin. 
2. MATERIALS AND METHODS 
The substrates used included Z-Ala-Lys-Arg- 
AMC (Enzyme System Products), human ACTH 
1-39 (purified in this laboratory from human 
pituitaries [3]), and bovine pro-enkephalin-derived 
peptides such as peptide B (Peninsula Labs) and 
the 8.6 kDa enkephalin precursor of struc- 
ture synenkeph~in-Lys-Lys-Tyr-Gly-Gly-Phe-Met 
which was purified from adrenal medulla as 
described [ 13 1. Bovine parathyroid chromogranin 
A (also known as parathyroid secretory protein 1) 
was purified as in [14]. 
The ‘251 labeling of ACTH l-39 and 
chromogranin A was done by the lactoperoxidase 
method followed by HPLC purification of the *‘?- 
1abeIed peptides [3]. All HPLC purifications were 
done on a Vydac protein C4 column (0.46 x 25 cm) 
eluted with a linear gradient of heptafluorobutyric 
acid (0.13 % , HFBA)/CH&N as described [3 1. For 
analysis of 1251-labeled peptides an on-line radioac- 
tivity flow detector (Flo-One, Radiomatic In- 
struments) was connected at the exit of the C4 
column [3]. 
The proteases used included TPCK-trypsin 
(Worthington), porcine anterior pituitary IRCM- 
SPl [l--3] and human IRCM-SPl (Seidah et al., in 
preparation). All incubations were done at room 
temperature in a final concentration of buffer con- 
taining 200 mM Bes, 2 mM EDTA, pH 8.5. One 
unit of enzyme activity (U) is defined as the 
amount of protease necessary to release 1 pm01 
AMC/s from the Z-Ala-Lys-Arg-AMC substrate 
at 42 yM in a buffer containing 100 mM Bes and 
1 mM EDTA at pH 8.5. 
Initial rate assays on the release of fluorescent 
AMC from Z-Ala-Lys-Arg-AMC (ranging from 10 
to 175 PM) by either trypsin (45.03 U) or porcine 
IRCM-SPl (41.82 U) were done as described [2] in 
a final volume of 500& The effect of 
chromogranin A (4 and/or 8 FM) was also studied. 
30 min digestions of ‘*%ACTH l-39 were done 
in duplicate with human IRCM-SPl (4.86 U) with 
various concentrations of unlabeled ACTH l-39 
(300, 500 and 700 FM in 50 rl), maintaining a con- 
stant specific activity (43000 cpm/nmol) either in 
the absence (control) or presence of 4OpM 
chromogr~in A. Here, analysis of the reaction 
products by HPLC/radioactivity detection reveal- 
ed the release of ACTH 18-39 (CLIP) and 1-17 as 
reported [3]. The integration of the CLIP peak 
allowed the calculation of the velocity of the reac- 
tion, taking into account that the tyrosines at posi- 
tions 2 and 23 of ACTH are labeled in a ratio of 
60:40 [3]. 
Amino acid analysis of the reaction products of 
peptide B obtained following digestion by IRCM- 
SPl and HPLC purification defined the exact 
cleavage as being C-terminal to the Lys-Argl bond 
producing the heptapeptide Tyr-Gly-Gly-Phe-Met- 
Arg-Phe (see fig. 1). Therefore, peptide B (50, 100, 
200, 300 PM in 50~1) was digested with human 
IRCM-SPl (5.56 U) for 30 min, the reaction pro- 
ducts purified by HPLC and then quantitated by 
UV absorption at 230 nm, relative to a standard 
heptapeptide. This permitted the calculation of the 
velocity of the release of this heptapeptide from 
peptide B, and the influence of chromogranin A 
(25 and 15 PM) on this reaction. 
The digestion of the 8.6 kDa pro-enkephalin 
precursor was performed in a final volume of 25 ~1 
(final concentration 2pM) in the Bes/EDTA (pH 
8.5) buffer with 3.7 U human IRCM-SPI with (0.2 
and 4pM) or without chromogranin A. At 0, 10, 
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20 and 30 min intervals, 5 ~1 aliquots were diluted 
with 2 vols glacial acetic acid and boiled for 
20 min. After evaporation, the released Met- 
enkephabn (Tyr-Gly-Gly-Phe-Met) was measured 
by radioimmunoassay as in [ 151. 
The digestion of 2 nmoi “‘1-chromogranin A 
(500000 cpm/nmol) with human IRCM-SPl 
(4.2 U) was done for 30 and 60 min at room 
temperature in a final volume of 50 ~1 (i.e. 40 pM 
chromogranin A), in either the absence or presence 
of 7OOpM ACTH l-39. A control incubation of 
chromogranin A in buffer was also made. Analysis 
of the digestion products was done on SDS-PAGE 
using 10% acrylamide separating gel, under non- 
reducing conditions, as described [2]. The 
separated bands were stained with Coomassie 
brilliant blue, the gel was then dried and 
autoradiography was performed as in [2]. 
3. RESULTS 
When chromogranin A was initially tested for its 
possible effect on the IRCM-SPl digestion of 
ACTH, it was found that concentrations below 
10,~M had no appreciable effect. However, at 
30 PM chromogranin A, a clear inhibitory effect 
was observed on the previously reported [3] con- 
version of ACTH into ACTH 1-17 and CLIP. 
Also, it was found that the addition of Ca2+ (up to 
5 mM) did not appreciably affect the inhibitory 
potency of chromogranin A. In order to study 
systematically such an inhibition, and to test its 
generality, it was decided to compare a number of 
different substrates in terms of the susceptibility of 
their IRCM-SPl cleavage to chromogranin A in- 
hibition. 
In fig.1 is shown the effect of 25 FM 
chromogranin A on the human IRCM-SPl 
cleavage of pro-enkephalin peptide B 1161. The 
amino acid composition of the cleavage products 
clearly showed that IRCM-SPl cleaves the 
3i-amino-acid peptide B C-terminal to Lys-Argl 
to generate the heptapeptide Tyr-Gly-GIy-Phe- 
Met-Arg-Phe and the N-terminal l-24 segment. In 
brain, the heptapeptide has been reported to repre- 
sent a major product of pro-enkephalin processing 
[17], implying a similar cleavage of peptide B in 
vivo. As seen in fig. lB, 25 FM chromogranin A is 
sufficient to inhibit more than 80% of this 30 min 
cleavage reaction. 
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Fig. 1. Reverse-phase HPLC of a 30 min human IRCM- 
SPl digest of 3OO/rM of the 31-amino-acid bovine pro- 
enkephalin peptide B (sequence FAEPLPSEEEGESY- 
SKEVPEMEKRYGGFMRF) (Bi-31) in the absence (A, 
control) or presence of 25 pM chromogr~in A (B). The 
dashed line represents the CH&N gradient. The identity 
of the released heptapeptide YGGFMRF and the N- 
terminal segment Bt-24 is based on the amino acid 
composition of the material eluting under these peaks. 
Under these conditions, chromogranin A inhibits by 
more than 80% the Lys-Argl cleavage of peptide B. 
The chromogranin A inhibition was also tested 
on either the porcine IRCM-SPl or trypsin 
cleavage of the fluorogenic substrate Z-AIa-Lys- 
Arg-AMC to release AMC. As shown in fig.2A 
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Fig.2. Double-reciprocal plot of the kinetic data 
obtained for the digestion of Z-Ala-Lys-Arg-AMC (A), 
human ACTH (B) and bovine pro-enkepohalin peptide 
B (C). The concentrations of chromogranin A are 
indicated in each graph. The kinetic parameters for each 
study are reported in table 1. 
and table 1, such an inhibition was found to be 
non-competitive, whereby increasing concentra- 
tions of chromogranin A (4 and 8pM) seem to 
decrease the maximum velocity of the reaction 
(I’,,) but have little effect on the K,. Interesting- 
ly, a similar inhibition pattern was observed on the 
trypsin cleavage of this substrate (table 1). This 
suggests that the inhibitory effect of chromogranin 
A is not selective for IRCM-SPI, and that the Iat- 
ter can interact with the catalytic chain of IRCM- 
SPl. As controls, we have tested whether other 
acidic proteins could also affect these cleavage 
reactions. However, our results demonstrated that 
neither human serum albumin (up to IOpM) nor 
hen ovalbumin (up to 12 /rM) had any detectable 
effect on either trypsin or IRCM-SPl cleavage of 
Z-Ala-Lys-Arg-AMC (not shown). 
When the chromogranin A inhibition of either 
ACTH or peptide B was studied kinetically, it was 
found that in both cases the inhibition was of a 
competitive type (fig.2B,C and table l), i.e. addi- 
tion of chromogranin A to the reaction medium 
caused an increase in Km but did not appreciably 
affect the I’&. This would mean that 
chromogranin A and either ACTH or peptide B 
compete for the same active site of IRCM-SPl. 
Notably, the IRCM-SPI cleavage of peptide B was 
found to be more sensitive than that of ACTH to 
chromogranin A inhibition (see fig.2B,C and table 
1). Since binding of chromogranins to pro- 
hormones has been suggested [Is], these data 
might reflect a differential affinity of 
chromogranin A for either ACTH or peptide B. 
Since chromogranin A is found in high concen- 
trations in chromaf~n cells of the adrenal medulla 
[7-91 it was of interest o find out whether it could 
also inhibit the IRCM-SPl cleavage of the 8.6 kDa 
pro-enkephalin precursor isolated from chromaf- 
fin granules 1131. IRCM-SPl cleaves the 8.6 kDa 
precursor at a single Lys-Lysl bond releasing Met- 
enkephalin and synenkephalin-Lys-Lysl (Metters 
et al,, in preparation). When such a reaction was 
performed in the presence of as little as 0.4,~M 
chromogranin A a high degree of inhibition was 
observed over at least 30 min (fig.3). These data 
show that the IRCM-SPl cleavage of the 8.6 kDa 
pro-enkephalin precursor is exquisitely sensitive to 
the presence of chromogranin A even at a mole 
ratio of 8.6 kDa precursor to chromogra~n A of 
5:l. 
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Table 1 
Kinetic parameters for the hydrolysis of Z-Ala-Lys-Arg-AMC by either porcine IRCM-SPl or 
trypsin, and of ACTH and peptide B by human IRCM-SPl 
[Chromo- 
granin A] 
(M) 
(x 106) 
V Vmax/Km 
(& (mol.U”_a.s-I) (mol.LJ-L.s-l.M-L) 
(x 106) (x 1012) (x 109) 
Trypsin 
Z-Ala-Lys-Arg-AMC 0 
8 
IRCM-SP 1 
Z-Ala-Lys-Arg-AMC 0 
4 
8 
Human ACTH l-39 0 
40 
Bovine peptide B 0 
15 
30.5 f 1.6 0.40 + 0.01 12.98 
27.2 + 2.8 0.30 + 0.01 11.17 
35.8 + 3.2 0.53 * 0.02 
33.7 * 3.3 0.42 f 0.02 
35.1 f 1.7 0.37 f 0.01 
817 f 166 1.92 f 0.24 
1136 + 117 1.88 f 0.13 
83 f 24 0.40 f 0.05 
455 f 26 0.40 f 0.01 
14.93 
12.46 
10.61 
2.35 
1.65 
4.84 
0.88 
Values were obtained by fitting the data with a Kinfit program [20] and expressed with the standard 
deviation of the fit 
Since the above data suggest that chromogranin 
A is a competitive inhibitor of IRCM-SP 1 cleavage 
of ACTH, peptide B, and possibly the pro- 
Fig.3. Time study of the IRCM-SPI release of the C- 
terminal Met-enkephalin from the 8.6 kDa pro- 
enkephalin precursor involving a Lys-Lysl cleavage, in 
the absence (control) or presence of 0.4 and 2gM 
chromogranin A. 
enkephahn 8.6 kDa precursor, it could itself serve 
as a substrate for this enzyme. Indeed, sequence 
data demonstrate that 8 pairs of basic amino acids 
are found in chromogranin A [lO,l 11, potentially 
representing cleavage sites for IRCM-SPl . As 
shown in fig.4, IRCM-SPl can cleave 
chromogranin A into smaller fragments, as yet un- 
characterized, migrating with an apparent 
molecular mass on SDS-PAGE (under non- 
reducing conditions) of 68 kDa (major), 59 kDa 
and 55 kDa. Also shown is the inhibiti’on of the 
chromogranin A cleavage by ACTH (see fig.3, 
lanes 3,6). These data clearly confirm that 
chromogranin A is a competitive inhibitor of 
ACTH cleavage by IRCM-SPI. However, the 
presence of more than one cleavage site on 
chromogranin A is expected to complicate the in- 
terpretation of the kinetic inhibition data. Indeed, 
for the 8.6 kDa precursor, the plot of the 
reciprocal of the velocity vs inhibitor concentra- 
tion is not linear (not shown), indicating a complex 
mechanism of interaction of chromogranin A and, 
possibly its cleavage products, with the substrate 
and enzyme. 
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Fig.4. SDS-PAGE analysis (under non-reducing 
conditions) of a 30 min IRCM-SPl digest of 
chromogranin A/“~1-chromogranin A mixture in the 
absence (lanes 2,s) and presence (lanes 3,6) of ACTH. 
Lanes l-3 represent he Coomassie blue coloration of 
the gel, and lanes 4-6 the corresponding autoradiogram. 
Lanes 1 and 4 show the migration of the control 
chromogranin A, which in this system migrates as an 
85 kDa band. The large band seen at the bottom of lane 
3 is the position of unlabeled ACTH in this system. 
Although not shown, a similar but less apparent 
inhibition is seen after 1 h reaction time, possibly due to 
extensive digestion of ACTH and chromogranin A on 
that time scale. 
The hypothesis 
serious candidate 
that IRCM-SPl represents a 
for a pro-hormone processing 
enzyme at both pairs and single basic residues 
[l-4] is now reinforced since we showed it to 
cleave precursors related to pro~~kephalin at sites 
expected from in vivo derived products. However, 
as previously noted (2-41, since IRCM-SP 1 cleaves 
all the bonds known to be processed in vivo, tissue- 
specific processing of pro-hormones [6,17] has to 
involve another factor(s) controlling the velocity of 
cleavage. This work suggests that chromogranin 
A, and possibly the other members of this family, 
4. DISCUSSIGN 
can participate in the biosynthetic pathway of pro- 
hormones leading to the final peptide forms that 
are secreted by a given tissue. The extent of this 
pa~icipation would depend on the relative concen- 
tration of chromogranin with respect to pro- 
hormones within the secretory granules and its 
binding affinity to the pro-hormone structure. For 
example, since ACTH is not appreciably cleaved in 
the anterior lobe of the pituitary but mostly 
cleaved in the intermediate lobe [6J, one would ex- 
pect that there are different amounts of chromo- 
granins in the corticotrophs of the two lobes. 
However, exact quantitative data on the amounts 
of chromogranins between these different cells are 
not yet available [18]. Furthermore, in the adrenal 
medulla one finds predominantly large molecular 
mass pro~nkephalin fragments [17,19], as op- 
posed to brain where mostly enkephalins are found 
1161. Since the chromogranin content within 
chromaffin granules is very high, possibly in the 
0.1-10 mM range [7-9,181, and certainly higher 
than in brain, this could explain the difference in 
the extent of pro-enkephalin processing between 
the adrenals and hypothalamus. Clearly, more 
work will be necessary to confirm fully the 
chromogranins’ potential inhibitory action on pro- 
cessing enzymes. However, the data presented here 
suggest an important role for chromogranin A as 
a regulator of post-translational processing of pro- 
hormones. 
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